Shopping Cart 0
Cart Subtotal
USD 0

Premenstrual Syndrome - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Premenstrual Syndrome-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome-Pipeline Review, H2 2018, provides an overview of the Premenstrual Syndrome (Women's Health) pipeline landscape.

Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman's menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premenstrual Syndrome-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Premenstrual Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively.

Premenstrual Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Premenstrual Syndrome (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Premenstrual Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Premenstrual Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Premenstrual Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Premenstrual Syndrome (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Premenstrual Syndrome (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Premenstrual Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premenstrual Syndrome-Overview

Premenstrual Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Premenstrual Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premenstrual Syndrome-Companies Involved in Therapeutics Development

Asarina Pharma AB

Pherin Pharmaceuticals Inc

Premenstrual Syndrome-Drug Profiles

(estrogen + progesterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80PMD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepranolone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 to Antagonize GABAA Receptor for PMDD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Antagonize GABAA Receptor for PMDD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premenstrual Syndrome-Dormant Projects

Premenstrual Syndrome-Product Development Milestones

Featured News & Press Releases

Aug 30, 2018: Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

Jul 09, 2018: Chief Medical Officer appointed for clinical trials of world's first therapy targeting both PMDD and menstrual migraine

Apr 24, 2018: First patients begin Phase IIB trials of world's first-ever therapy developed specifically to treat PMDD

Apr 24, 2018: First patients begin Phase IIB trials of world's first-ever therapy developed specifically to treat PMDD

Apr 06, 2018: Asarina Pharma announces the start of a clinical Phase IIB study in patients with premenstrual dysphoric disorder

Apr 04, 2018: Asarina Pharma starts recruiting patients for Phase IIB clinical trial of Sepranolone, the world's first treatment specifically targeting PMDD (premenstrual dysphoric disorder), the severest form of PMS

Apr 03, 2017: Asarina Pharma Phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint.

Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)

Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder

Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood's candidate drug for severe premenstrual symptoms

May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Premenstrual Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Premenstrual Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Premenstrual Syndrome-Pipeline by Asarina Pharma AB, H2 2018

Premenstrual Syndrome-Pipeline by Pherin Pharmaceuticals Inc, H2 2018

Premenstrual Syndrome-Dormant Projects, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Premenstrual Syndrome Therapeutic Products under Development, Key Players in Premenstrual Syndrome Therapeutics, Premenstrual Syndrome Pipeline Overview, Premenstrual Syndrome Pipeline, Premenstrual Syndrome Pipeline Assessment


Companies

Asarina Pharma AB

Pherin Pharmaceuticals Inc